ArticleJournal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS)2025
Transcriptomic analysis of Cr(VI)-induced changes in C2C12 cells during myogenic differentiation.
Article in Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundHexavalent chromium [Cr(VI)] is an environmental toxicant extensively used in a variety of industrial processes including chrome plating, leather tanning, textile manufacturing, aircraft production, and stainless-steel production. Our previous study reported that exposure to Cr(VI) inhibited C2C12 myogenic differentiation in a dose-dependent manner, yet the transcriptional mechanisms underlying Cr(VI)-induced disruption of myogenesis remains poorly understood. This study aimed to characterize the global transcriptional alterations during C2C12 myogenic differentiation and identify molecular pathways disrupted upon Cr(VI) exposure.
methodsC2C12 cells were differentiated in the presence of 0, 2, or 5 μM of Cr(VI) and collected at differentiation days 0, 1, 2, and 4. Whole transcriptome analysis of a total of 30 samples (with 3 biological replicates per condition) was performed using RNA-sequencing followed by differential gene expression analysis, unsupervised fuzzy c-means clustering, GO biological processes functional annotation, and KEGG pathway enrichment analysis.
resultsCr(VI) exposure resulted in a massive transcriptomic change in differentiating C2C12 cells. Fuzzy c-means clustering identified 12 distinct gene expression patterns, with Clusters 3, 10, and 12 showing significant overlap with Cr(VI)-regulated genes. Functional enrichment analyses revealed Cr(VI) alters genes involved in early-stage cell cycle regulation and DNA repair as well as terminal differentiation processes like sarcomere organization and muscle contraction. Specifically, Cr(VI) suppressed expression of key structural and contractile genes and disrupted pathways essential for myogenic differentiation, cell cycle regulation and DNA damage repair. Furthermore, Cr(VI) disrupted Hippo signaling by downregulating Tead4 and its downstream myogenic targets such as MyoG, Cav3, Mustn1, and Dysf suggesting a mechanism for impaired differentiation.
conclusionThis study highlights the widespread alterations of Cr(VI) exposure on transcriptional programs - including structural development, genomic stability, and cell cycle withdrawal - governing muscle development and maturation, offering insight into how Cr(VI) exposure affects skeletal muscle health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.